Platelet Count Below 100,000/mm³ is an Absolute Contraindication to TNK for Acute Ischemic Stroke
A platelet count below 100,000/mm³ (100 × 10⁹/L) is classified as an absolute contraindication (Class III: Harm) to thrombolytic therapy, including tenecteplase (TNK), for acute ischemic stroke. 1
Guideline-Based Recommendation
The 2018 AHA/ASA Guidelines explicitly state that "The safety and efficacy of IV alteplase for acute stroke patients with platelets <100,000/mm³...are unknown, and IV alteplase should not be administered" (Class III: Harm; LOE C-EO) 1. While these guidelines specifically reference alteplase, the same contraindication applies to tenecteplase given their shared mechanism as thrombolytics and similar bleeding risk profiles.
The FDA label for tenecteplase does not list a specific platelet threshold as a contraindication, but does list "known bleeding diathesis" as an absolute contraindication 2. Thrombocytopenia below 100,000/mm³ functionally represents a bleeding diathesis.
Practical Clinical Algorithm
If platelet count is unknown:
- You may initiate thrombolytic therapy in patients without a history of thrombocytopenia
- However, you must discontinue the infusion immediately if the platelet count returns <100,000/mm³ 1
If platelet count is known to be <100,000/mm³:
- Do not administer TNK or any thrombolytic
- Consider mechanical thrombectomy alone if the patient is otherwise eligible
Evidence Nuances and Caveats
While the guideline classification is clear, limited real-world data suggests the actual bleeding risk may be lower than feared. A small case series of 26 thrombocytopenic patients (mean platelet count 63,000/mm³) who received IV thrombolysis showed a symptomatic intracranial hemorrhage (sICH) rate of 7.7%, which was not statistically different from patients with normal platelet counts (6.04%) 3. However, this represents only 26 total patients across all published literature—far too small to override guideline recommendations.
Critical pitfall: Do not delay treatment waiting for platelet results if there is no clinical suspicion of thrombocytopenia. The guidelines explicitly permit starting thrombolysis before lab results are available in patients without thrombocytopenia history, but mandate stopping if platelets return low 1.
Why This Matters for Morbidity and Mortality
The absolute contraindication exists because:
- Thrombocytopenia significantly impairs hemostasis
- Thrombolytics further compromise clot formation through fibrinogen depletion and systemic plasminogen activation
- The combination creates unacceptable hemorrhagic risk, particularly intracranial hemorrhage
- The potential for catastrophic bleeding outweighs uncertain stroke treatment benefit
In patients with platelets <100,000/mm³, mechanical thrombectomy remains a viable option and does not carry the same contraindication, allowing for reperfusion therapy without systemic thrombolytic exposure.